Table 3 Univariate and multivariate analysis of prognostic factors of overall survival for patients with metastatic urothelial carcinoma treated by first-line cisplatin-based chemotherapy (n = 103)

Sex

0.88

 Male

0.96 [0.57–1.6] 0.88

 Female

1

Age

0.34

 <64 years

1

 > = 64 years

0.82 [0.54–1.24] 0.34

PS

<0.001

 PS 0

1

1

 PS 1

2.11 [1.31–3.40] 0.002

2.3 [1.3–3.9] 0.002

 PS 2 or 3

4.98 [2.61–9.49] <0.001

3.4 [1.6–7.2] 0.001

Hb level (cut-off: 11g/dl)

0.03

 Normal

1

1

 Abnormal

1.65 [1.05–2.6] 0.029

1.7 [1.01–2.8] 0.045

Metastatic relapse

0.90

 No

1

 Yes

0.97 [0.62–1.51]0.90

N metastatic site

<0.001

 1

1

excluded p = 0.76

 2

1.63 [0.99–2.70] 0.054

 ≥3

2.87 [1.60–5.2] <0.001

Visceral metastases

<0.001

 No

1

1

 Yes

2.29 [1.4–3.7] 0.001

2.2 [1.3–3.9] 0.004

Chemotherapy regimen

0.18

 G-C

1

 M-VAC

0.60 [0.28–1.27] 0.18

 G-C and G-carboplatin

1.40 [0.77–2.55] 0.27

Response to treatment

0.002

 SD

1

1

 EOR (CR + PR)

0.93 [0.6–1.5] 0.75

1.45 [0.9–2.4] 0.16

 PD

3.2 [1.5–6.5] 0.002

10.1 [4.2–24.1] 0.000